Akkermansia muciniphila: a microbial guardian against oxidative stress–gut microbiota crosstalk and clinical prospects

Akkermansia muciniphila (A. muciniphila), a mucin-degrading commensal bacterium predominant in the gut microbiota, establishes a multifaceted antioxidant defense system through its enzymatic machinery and bioactive metabolites. The bacterium maintains mucosal homeostasis via specialized mucinolytic enzymes while secreting functionally diverse components including SCFAs, outer membrane proteins (notably Amuc_1100), and extracellular vesicles (EVs). Mechanistically, Amuc_1100 enhances SOD activity and reduces oxidative damage markers such as MDA through TLR2/NF-κB pathway activation. SCFAs mediate systemic antioxidant responses via gut-organ axis communication, while EVs ameliorate intestinal barrier dysfunction through MAPK signaling pathway modulation. Clinically, A. muciniphila supplementation demonstrates therapeutic efficacy in improving insulin sensitivity in obese and type 2 diabetic patients, and shows potential in mitigating Parkinson's disease pathology by regulating α-synuclein oligomerization. Translational applications face several challenges, including strain-specific functional variations, host microenvironment dependencies, and potential risks of excessive mucin degradation. Recent advances in bioengineering approaches, particularly microencapsulation and biomimetic delivery systems, have significantly enhanced bacterial viability and targeted delivery. Future investigations should employ integrated multi-omics strategies to elucidate the intricate metabolic-immune-redox regulatory networks of A. muciniphila, facilitating its development as a precision therapeutic intervention.